Introduction: There is an increasing interest for real-life data on drug use in many countries.
INTRODUCTION
The prevalence of type 2 diabetes mellitus (T2DM) is dramatically rising across the world, largely fueled by the epidemic of obesity and aging of the population [1] . The International Diabetes Federation (IDF) estimates that 382 million people have diabetes in 2013 and this will rise to 592 million by 2035 [2] . In the USA, 8 .3% of the population has T2DM [3] , close to the overall latest 2013-IDF estimated prevalence of 8.5% in Europe [4] . In France, diabetes affects 4-5% of the adult population [5] . Prevention and treatment of the disease and its complications pose a major burden on national healthcare systems worldwide, accounting for 12% globally of the health expenditures in 2010 [6] and thus constitute one of the most challenging global health issues of the twenty-first century.
In addition to lifestyle changes, effective and safe pharmacological therapies are needed to manage T2DM. Several new classes of antidiabetic agents have recently been introduced in the management of T2DM. The 2012 position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) reviews advantages and disadvantages of all available classes and proposes a patientcentered approach, taking into account patient preferences, effects on body weight and on hypoglycemia risk, cost and potential side effects of each class [7] . The latest 2013 HAS-French guidelines, however, recommend a more prescriptive algorithm with sequential choices essentially guided by long experience with the drugs and economic considerations [8] .
Vildagliptin is a member of the new class of dipeptidyl peptidase 4 (DPP4) inhibitors that work by maintaining high levels of endogenous incretins. This leads to improved sensitivity of a-and b-cells to glucose, which results in glucose-sensitive modulation of insulin and glucagon secretion [9] . Vildagliptin has been shown to improve both fasting and postprandial glycemic control in T2DM patients [10] with a low risk of hypoglycemia [11] , and is effective across a wide disease spectrum, from newly diagnosed patients [12, 13] to patients with long-standing T2DM [14] [15] [16] [17] . Indeed, the overall magnitude of glycosylated hemoglobin (HbA 1c ) reduction has been found to be more or less similar throughout treatment stages, when used in monotherapy [18] , in combination with one [10, 19, 20] or two oral antidiabetic drugs (OADs) [21] or with insulin [22] . A hypoglycemia risk similar to placebo has consistently been seen with vildagliptin [11] including in high-risk patients such as elderly patients [23] [24] [25] , patients with renal impairment (RI) [27] [28] [29] and/or patients treated with insulin [14, 30] .
While the drug has been extensively studied in multiple randomized clinical trials (RCTs), additional data from large, non-selected patient populations in the real-world environment are valuable complements, which may be more applicable to daily management of T2DM [31] .
In the present observational study, the authors have set out to evaluate the effectiveness, treatment persistence and tolerability of vildagliptin over 2 years following real-life prescription to patients with T2DM.
METHODS

Study Design
The VILDA study was a prospective, [32] subsequently, to measure satisfaction in relation to the change in therapeutic strategy. The overall DTSQs score is interpreted such that the higher the score, the greater the satisfaction (with a maximum at 36). The total DTSQc score ranges from -18 to ?18. Available biological data were collected at each visit (in addition to fasting plasma glucose and HbA 1c levels). They included creatinine levels and estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease (MDRD) formula [33] , transaminase levels and all lipid parameters.
All AEs and serious AEs (SAEs) together with their severity and relationship to the study treatment were documented at each visit and analyzed in the whole population recruited in the study.
Statistical Analyses
Quantitative or continuous variables were described by mean and standard deviation (SD) and in some cases median and range.
Qualitative variables were described by absolute frequency and percentage per modality.
Quantitative variables were compared between groups by Student tests in case of normal distribution and Wilcoxon-Mann-Whitney test otherwise. Qualitative variables were compared between groups using the Pearson Chi-square test if all theoretical sample sizes were C5 or using the Fisher test if \5. All tests were performed with a significance level of 5%. All statistical analyses were performed using SAS 9.2 software (SAS Institute, Cary, NC, USA).
To verify the representativeness of the physicians participating in the study, their characteristics were compared to those of all French physicians (age, gender, type and place of work). This analysis was performed separately for the GPs and for the endocrinologists.
Representativeness of the patients included in the study was checked by a comparison with patients of the non-inclusion registry, a comparison of patients whose treatment began in the \6 months prior to the inclusion date with patients included on the day of vildagliptin initiation, and a comparison of patients who did not complete the study with those followed-up throughout the entire study period over the four planned visits.
Patient data were analyzed separately according to physician specialty (general or specialist practitioners) and pooled without weighting the sample.
Sample size was set to guarantee sufficient accuracy of the proportion of patients meeting the conditions of use of vildagliptin (estimated at 50%). A cohort of 1,000 patients allowed to estimate this proportion with a precision of about 3% at a confidence level of 95%; to take into account an expected *20% drop-out rate over 2 years, the sample size was thus set at 1,300 patients needed to be included in the study.
Compliance with Ethics
All procedures followed were in accordance with the ethical standards of the French Order 
RESULTS
Patient's Flow Chart and Baseline Characteristics
A total of 1,763 patients were enrolled in the study, 1,700 were kept in the initial analysis and 1,639 in the follow-up analysis (see Fig. 1 for patients' flow chart). The mean follow-up period was 22.9 months, with 80.6% of patients followed for C22 months.
Of the 1,700 patients, 26% were treated with vildagliptin and 74% with the fixed vildagliptin-metformin combination. 37.8% of patients had started vildagliptin within the previous 6 months and 62.2% started vildagliptin on the day of inclusion.
Of the 567 investigators (483 GP and 84 SPE) who included at least one patient, 392 (337 GP and 55 SPE) returned the registry of noninclusion (n = 1,457 patients). The comparison between these 1,457 patients with those included in the study did not identify any potential selection bias, though patients included in the study were slightly younger (62.5 years). The reasons for not including patients were: patient's refusal to participate (41%), anticipated difficulties for the follow-up (37%), no time to include the patient at the time of the visit (17%) and other reasons (5%). included by male and female GP were thus compared, and this analysis did not identify any significant difference between these two populations.
Characteristics of the VILDA Population
Patients' demographic characteristics together with details of their diabetes are presented in Safety data were collected on all the 1,763 patients included in the study. Table 2 summarizes the frequency of all AEs, SAEs and events suspected to be related to the vildagliptin treatment. Overall, nearly 20% of patients conducted to monitor the health status of adult diabetic patients from a representative sample of French diabetic patients pharmacologically treated [34] ), even if the T2DM patients included in VILDA study were inherently different in that they were seen at the time of treatment intensification. VILDA participants were slightly younger (63 years vs. 66 years in ENTRED), predominantly male (60% vs. 53%), and their diabetes was more recent (mean duration from diagnosis of 7 vs. 9 years). The proportion of obese persons was close (45% and 41%, respectively in VILDA and ENTRED), as was that of smokers (19% and 16%, respectively) and of patients receiving antihypertensive therapy (70% and 75%).
Erectile dysfunction was reported for 22.8% of men in the VILDA study, a fairly comparable rate to the 25% of ENTRED. Mean HbA 1c was higher as expected (7.8% vs. 7.1% overall in ENTRED), since VILDA participants were included at time of treatment intensification and thus frequently had unsatisfactory glucose control.
The mean HbA 1c level of 7.8% at time of treatment intensification in VILDA was remarkably consistent with other real-life studies conducted in France (HYPOCRAS [35] ) or in Germany [36] , where the mean level before addition of a second agent was identical. While in the large, worldwide EDGE (Effectiveness of Diabetes control with vildaGliptin and vildagliptin/mEtformin) study [31] , the overall mean HbA 1c recognized as monotherapy failure before the addition of a second OAD, was slightly higher (8.2%), it was again very similar in Europe. The DIATTITUDE study [37] further looked into the behavior of French GP vis-à-vis intensification of oral antidiabetic agents in T2DM patients, according to their HbA 1c level. 41% of patients had unsatisfactory glucose control (47%, 39% and 20%, respectively, in monotherapy, dual therapy and C triple therapy), with an overall mean HbA 1c of 7.5% (7.2%; 7.8% and 9.0%, respectively, in monotherapy, dual therapy and C triple therapy). Of these patients, however, only 7% had their treatment intensified after the visit. There were countless reasons for postponing the pharmacological intensification, many of them legitimate such as reinforcing lifestyle advices first or improvement by comparison with the last measure of glycemic control, but the so-called ''therapeutic inertia'' was also often in play [37] .
The efficacy results observed in real-life in the VILDA study were thoroughly consistent with those obtained during the RCTs. HbA 1c decreased from a mean baseline of 7.8% to a mean of 7.0% at the first follow-up visit at 6 months and this reduction was then maintained over the 2 years of the VILDA study. Similar results were observed in the subgroup treated exclusively with vildagliptin in dual therapy with metformin and who were prescribed this treatment combination throughout the study without any other drug.
In RCTs, patients were recruited worldwide and were on average slightly younger, tended to be more obese, and often presented with higher HbA 1c [26, 38] , with some exceptions [19] . In the main registration study in add-on to metformin, a reduction of -0.9% was seen from a mean baseline of 8.4% [10] , while in another trial in add-on to metformin starting from a much lower baseline of 7.3%, mean
HbA 1c decreased to 6.8% by weeks 12 with vildagliptin and remained essentially stable thereafter with a mean HbA 1c of 6.75% at week 52. This illustrates the well known and typical trend of greater HbA 1c reductions seen from higher baseline levels [39] . A pooled analysis of phase 3 studies also showed mean changes in HbA 1c with vildagliptin of -0.9% from a mean baseline of 8.4% in add-on to [26] . Further analysis in add-on to metformin showed that efficacy was about the same regardless of BMI, disease duration or duration of metformin use, with significant drops in HbA 1c of approximately -0.7% from a mean baseline of 7.7% [15] . This is actually similar to the results in VILDA from a similar baseline, in the overall population and in the main subgroup treated in dual therapy with metformin. In addition, the results of the VILDA study highlight the durability of effects over 2 years, which was also seen in RCTs [20, 40] . Hypoglycemia is one of the main limitations for glucose-lowering therapy and also a key factor underlying clinical inertia [41] . Low hypoglycemic risk is an essential feature of the DPP4-I class of drugs and has been largely documented in clinical trials with vildagliptin [11] , stemming from a strong mechanistic rationale [42] . In a recent German database study, DPP4-I use was associated with a fivefold reduced frequency of patients with hypoglycemia compared to sulphonylureas (SU) [43] . In the French HYPOCRAS study [35] , the proportion of T2DM patients (of mean age 71) reporting hypoglycemia over 6 months was 6.4% with a DPP4-I vs. 26% with SU or glinides, and that of severe hypoglycemic events was, respectively, 0.1% vs. 3.2% (p\0.001). In keeping with these data, the improvement in glycemic control in the VILDA study was not associated with an increased risk of hypoglycemia, the incidence of which remained very low over 2 years. Moreover, severe hypoglycemic episodes were observed exclusively in combination with insulinsecreting treatment (SU and/or glinides) and/ or with insulin, and symptomatic episodes were reported primarily in patients concomitantly treated with SU and/or glinide and/or insulin.
Among patients previously treated with SU and/or glinides before starting vildagliptin, the proportion of those reporting a history of severe hypoglycemia was 3.7%. This figure is fairly comparable to that found in the literature: in the HYPOCRAS study, 3.2% of patients treated with an SU or glinide experienced an episode of severe hypoglycemia over the 6-month study period [35] . In the ENTRED study, 5% of subjects' C65 years treated with SU reported at least one episode of severe hypoglycemia over a period of 1 year [44] . Severe hypoglycemia has been associated with a higher risk of cardiovascular disease, and this association did not seem to be solely explained by comorbid severe illness [45] . Research also demonstrated the impact of hypoglycemia, as well as fear of hypoglycemia, on quality of life, related outcomes and healthcare utilization of people with T2DM [46, 47] . In a recent prospective observational study carried out as an addendum to a mandatory study of the Italian Medicine Agency (AIFA), the fixed combination vildagliptin/metformin over 1 year was shown to improve patient satisfaction, quality of life (DTSQ) and work productivity measured as Work Productivity and Activity Impairment (WPAI) scores [48] .
An important dimension that needs to be taken into account is the adherence to prescribed medications. Discontinuation of antidiabetic therapy results in substantial costs for the healthcare system and appears to be frequently found in primary care patients. The ENTRED survey examined medication adherence using a 6-item self-administered questionnaire in 3,637 persons with T2DM: 61% of patients reported medium to poor adherence [49] . This level of medication adherence was unexpectedly low in France, a country with a high level of access to healthcare. In a database study conducted in 1,201 general practices in Germany [43] , therapy persistence with DPP4-I (19,184 users) and SU (31,110 users) was compared. Two years after index date, DDP4-I was associated with a lower risk of discontinuation compared to SU (39% vs. 49%) [adjusted hazard ratio (HR) 0.74; 95% CI 0.71-0.76] [43] . In view of these data, the treatment maintenance rate in the VILDA study at 2 years was very satisfactory at 88.8% (95% CI 87.2-90.4%) in line with the improved satisfaction reported with treatment (?9 at the DTSQc), and the good and well-maintained efficacy with few tolerability issues (4% of patients discontinued treatment for adverse events over the entire study period) and low hypoglycemia risk.
This study is also consistent with other reallife studies worldwide. The largest-scale study was EDGE, a 1-year, prospective study of more than 45,000 patients with T2DM not reaching glycemic targets with monotherapy, conducted in 27 countries from Europe, Central and Latin America, Asia and Middle East [31] . Physicians could add vildagliptin (vildagliptin cohort) or any other OAD (pooled comparator cohort). The primary end-point (proportions of patients   with HbA 1c decrease [0.3%, without hypoglycemia, weight gain, peripheral edema or gastrointestinal side-effects) was attained more frequently in the vildagliptin vs. the comparator cohort, with an adjusted odds ratio of 1.49 (95% CI 1.42, 1.55; p\0.001). In this setting, vildagliptin as second OAD lowered HbA 1c by about 1% from a mean baseline of 8.2%. Other DPP4-I have been studied as well in real-life conditions, such as sitagliptin in the SUGAR study [50] , a large Belgian prospective observational study of shorter duration.
This study has usual strengths and limitations.
Physician participation was decided on a voluntary basis, which constitutes a classic potential selection bias in this type of study. However, the investigators were representative of all French GP and SPE across several characteristics, with the exception of a slightly higher proportion of men among the VILDA investigators. Another potential selection bias comes from the fact that the treating physician chooses which patient was included into the study. However, comparison of the patients included with patients from the non-inclusion registry did not reveal any bias that might affect the results of this study. Thus, these data can be considered as reliable and nicely representative of current care delivery to diabetic patients treated with vildagliptin in France. Some patients were lost during the follow-up. However, the rate of 80.6% of patients followed over 2 years is satisfactory, in line with the authors' statistical hypothesis, and compares well with other studies of identical design, such as AVANCE where this rate was 62.4% [51] . Finally, the quality of data collection in observational studies is always questioning. The quality of the data collection was assessed during the survey auditing collected files in a 5% random sample of all enrolled patients. Audit results were positive not showing serious irregularities or anomalies.
CONCLUSION
The present study provides important information for management of T2DM in daily practice, as it emphasizes the effectiveness of vildagliptin treatment, with a low risk of hypoglycemia and fairly good persistence at mid-term, in a large population of patients in the real-world environment. It confirms the results obtained under controlled conditions in selected patients from RCTs.
